Antibody-Drug Conjugates in Cancer Treatment
EP. 1: Overview of Antibody-Drug Conjugates (ADCs)
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).
EP. 2: Mechanisms of Action of Antibody-Drug Conjugates
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.
EP. 3: Molecular Testing in Breast Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.
EP. 4: Biomarker Testing in Gastrointestinal and Lung Cancers
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.
EP. 5: Molecular Testing Considerations in Cancer Treatment
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.
EP. 6: Best Practices for Patient Education Surrounding Cancer Treatment
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.
EP. 7: Antibody-Drug Conjugates in Breast Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.
EP. 8: Toxicity Management for T-DM1 and T-DXd in Breast Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].
EP. 9: Antibody-Drug Conjugates in Lung Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.
EP. 10: Management of ADC Toxicities in Lung Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.
EP. 11: Gastric Cancer Treatment: T-DXd
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
EP. 12: Managing T-DXd Toxicities in Gastric Cancer
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
EP. 13: Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
EP. 14: TROP2-Targeting Antibody-Drug Conjugates
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
EP. 15: Treatment Considerations With TROP2-Targeted Therapy
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Clinical insights on best practices for treating patients with TROP2-targeted therapy.
EP. 16: Future Directions in Gastric Cancer Treatment
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
EP. 17: Future Outlook for Treating Breast and Lung Cancers
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
EP. 18: Educating Community Specialists on Evolving Treatment Landscape
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
EP. 19: Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape
ByBenjamin P. Levy, MD,Michal F. Segal, RN,Benjamin Leon Musher, MD,Rasheda Persinger, MSN, AGNP-C, AOCNP,Kevin Kalinsky, MD, MS,Kayla Freeman, DNP, APRN, FNP-C The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
